Immune-mediated cholangitis: is it always nivolumab’s fault?

  • Francesco Gelsomino
  • Giovanni Vitale
  • Andrea Ardizzoni
Letter to the Editors
  • 25 Downloads

Notes

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

References

  1. 1.
    Kashima J, Okuma Y, Shimizuguchi R, Chiba K (2018) Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother 67:61–65.  https://doi.org/10.1007/s00262-017-2062-3 CrossRefPubMedGoogle Scholar
  2. 2.
    Kawakami H, Tanizaki J, Tanaka K et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529–536CrossRefPubMedGoogle Scholar
  3. 3.
    Gelsomino F, Vitale G, D’Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28:671–672CrossRefPubMedGoogle Scholar
  4. 4.
    European Association for the Study of the Liver (2009) EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51:237–267CrossRefGoogle Scholar
  5. 5.
    Haanen JBAG., Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, ESMO Guidelines Committee (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv119-iv142CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Francesco Gelsomino
    • 1
  • Giovanni Vitale
    • 1
  • Andrea Ardizzoni
    • 1
  1. 1.Medical Oncology UnitPoliclinico S. Orsola-Malpighi, University of BolognaBolognaItaly

Personalised recommendations